|Mr. Raymond W. Cohen||CEO & Director||1.22M||N/A||1959|
|Mr. Danny L. Dearen||Pres & CFO||447.58k||N/A||1963|
|Mr. Rinda K. Sama||Chief Operating Officer||577.9k||N/A||1979|
|Dr. Karen L. Noblett M.D., M.A.S.||Chief Medical Officer||163.85k||N/A||1963|
|Mr. Guangqiang Jiang Ph.D.||Chief Technology Officer||N/A||N/A||1973|
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.
Axonics Modulation Technologies, Inc.’s ISS Governance QualityScore as of February 3, 2020 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 8.